SCHEDULE: T. Rowe Price Discloses 1.3% Stake in Apogee Therapeutics

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 772,969 shares, representing 1.3% of the outstanding common stock of Apogee Therapeutics Inc.

Summary

• T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, indicating it is a passive investor.
• The filing reports beneficial ownership of 772,969 shares of Apogee Therapeutics Inc. common stock.
• This ownership stake represents 1.3% of the class of securities.
• The filing was made on July 8, 2026, with the event date being June 30, 2026.
• T. Rowe Price Investment Management, Inc. is classified as an investment adviser.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the involvement of a large investment manager like T. Rowe Price can be positive, the Schedule 13G indicates a passive stake without providing operational or financial performance details of the company itself.

Positives

• T. Rowe Price Investment Management, Inc., a significant investment adviser, has taken a position in Apogee Therapeutics, which can be seen as a vote of confidence in the company's potential.
• The passive nature of the investment (as indicated by the Schedule 13G filing) suggests a long-term investment horizon rather than an activist approach.

Negatives

• The filing does not contain any negative information regarding the company's performance or operations.

Risks

• The filing does not explicitly mention any risks associated with Apogee Therapeutics Inc.

Future Outlook

The filing is a Schedule 13G, which reports passive ownership and does not contain forward-looking statements or guidance from Apogee Therapeutics Inc.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major investment manager like T. Rowe Price Investment Management, Inc. often signals institutional interest in a company, particularly in the biotechnology sector where significant growth potential exists. This filing indicates a passive investment, suggesting T. Rowe Price views Apogee Therapeutics as a potentially valuable holding without seeking to influence company control.

Stakeholder Impact

• Shareholders: The filing indicates increased institutional interest, which could potentially lead to greater market visibility and stability for the stock.
• Management: The passive nature of the investment suggests no immediate pressure for strategic changes from T. Rowe Price.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Apogee Therapeutics, T. Rowe Price, Schedule 13G, Investment Management, Beneficial Ownership, Common Stock, SEC Filing, Biotechnology